Pfizer Stock Eyes Rebound as Vaccine Bets Heat Up

Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock.

Pfizer is back on traders’ radar as Wall Street edges more positive on the stock while the company pushes a string of late‑stage vaccines and early‑stage drugs. Jefferies reiterated a Buy rating with a $34 price target versus Pfizer’s recent $26.77 close, and Street consensus now sits at a Moderate Buy with an average target around $29, implying mid‑single‑digit upside from current levels.

Investor attention is centering on Pfizer’s Lyme disease vaccine, co‑developed with Valneva, after a Phase 3 trial showed over 70% efficacy with no major safety issues in patients across the U.S., Canada, and Europe. Pfizer says it is confident in the asset and plans to file for regulatory approval, positioning the vaccine as a potential new revenue stream in an area with no existing shots.

The company is racing to offset looming patent expirations and weaker outlooks for COVID‑19 products, after booking a $7.8 billion net loss in 2025 and guiding to softer 2026 earnings. Management is leaning heavily on its pipeline, including the $10 billion Metsera acquisition to enter obesity, where its PF’3944 candidate has delivered encouraging trial results and is slated for a series of Phase 3 studies starting in 2026.

Beyond headline programs, Pfizer is quietly reshaping its portfolio with a mix of incremental and high‑risk R&D moves that may not swing earnings near term but could support longer‑term growth. Recent steps include a Phase 1 dosing study for PF‑07328948 in patients with liver impairment, a Phase 2 pediatric trial of etrasimod in ulcerative colitis, and life‑cycle work on tafamidis via a new tablet formulation.

Oncology remains a mixed picture: Pfizer scrapped a Phase 1 trial of PF‑08046031 for advanced solid tumors, underscoring the sector’s high attrition rate, while launching a fresh Phase 1 study of PF‑07994525 in heavily pretreated cancer patients. Meanwhile, investors are watching closely for data from a completed Phase 2 trial of the next‑generation PG4 pneumococcal vaccine in toddlers, which could extend Pfizer’s lucrative pediatric vaccine franchise if it outperforms Prevnar 20.

Despite these catalysts, sentiment is still cautious, with a broader Hold consensus on Pfizer’s shares based on recent analyst surveys and an average price target under $30 that implies only modest upside. For stock pickers, Pfizer now looks like a classic pipeline story: limited short‑term growth, but a growing list of shots on goal in vaccines, obesity, and immunology that could re‑rate the stock if upcoming data and regulatory decisions break in its favor.